Phenoperidine

Phenoperidine
Systematic (IUPAC) name
ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate
Clinical data
Routes of
administration		 Intravenous
Legal status
Legal status
Pharmacokinetic data
Metabolism Liver
Excretion Bile and Urine
Identifiers
CAS Number 562-26-5 N
ATC code N01AH04 (WHO)
PubChem CID 11226
ChemSpider 10752 YesY
UNII G9BH09J4JW YesY
KEGG D02611 YesY
Chemical data
Formula C23H29NO3
Molar mass 367.481
 NYesY (what is this?)  (verify)

Phenoperidine (Operidine or Lealgin), is an opioid used as a general anesthetic.

Medical use

Phenoperidine is an opioid pain killer -- narcotic analgesic.

Pharmacology

It is a derivative of isonipecotic acid, like pethidine, and is metabolized in part to norpethidine. It is 20-200 times as potent as pethidine as an analgesic. The greatly increased potency essentially eliminates the toxic effects of norpethidine accumulation which are seen when pethidine is administered in high doses or for long periods of time.

History and Synthesis

Phenoperidine was first synthesized in 1957 by Paul Janssen, of the company now known as Janssen Pharmaceutica, who was seeking better opioid pain-killers.[1] His two prototype drugs were methadone and pethidine, each which had been invented in 1930s by Otto Eisleb, who worked for IG Farben. His initial work starting with methadone yielded dextromoramide in 1954. Janssen then turned to making pethidine analogues, due in part to the less complicated chemistry of the compound. During his explorations, he replaced the methyl group attached to the pethidine nitrogen with a propiophenone group, and this yielded phenoperidine, in 1957. Phenoperidine was determined to have decreased stability and enhanced lipophilicity compared to pethidine. Soon after, studies in mice showed that phenoperidine was over 100 times more potent than pethidine.[1]

In 1958, the same line of work yielded “one of the greatest advances of the 20th century psychiatry", haloperidol,[1] as well as diphenoxylate, which lacked the opioid's analgesic properties but still stopped peristalsis in the intestines, a typical side effect of opioids; Janssen brought diphenoxylate to market as a drug to treat diarrhea.[2]:124 And through further advances, Janssen created fentanyl in 1960, which proved to be ten times more potent than phenoperidine.[3]

Historical Uses

In 1959, the combination of phenoperidine and haloperidol was first used in Europe in anesthesia to induce a detached, pain free state called Neuroleptic analgesia; the use of that mixture boomed in early 1960s but was overtaken by the combination of fentanyl and droperidol, which was widely used through the 1980s. These combination approaches were not adopted in the US.[4]:644

Regulations

In 1961 phenoperidine was added to the 1931 Convention for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs by the World Health Organization via the Single Convention on Narcotic Drugs.[5][6]

In the US it is classified as a schedule 1 opiate and is categorized as a Drug Enforcement Administration (DEA) controlled substance with a corresponding code 9641.[7]

References

  1. 1 2 3 Lopez-Munoz, Francisco; Alamo, Cecilio (2009). "The Consolidation of Neuroleptic Therapy: Janssen, the Discovery of Haloperidol and Its Introduction into Clinical Practice". Brain Research Bulletin 79: 130–141. doi:10.1016/j.brainresbull.2009.01.005. PMID 19186209.
  2. ↑ Walter Sneade. Drug Discovery: A History. John Wiley & Sons, 2005 ISBN 9780471899792
  3. ↑ Stanley, Theodore (2014). "The Fentanyl Story". The Journal of Pain 15 (12): 1215–1226. doi:10.1016/j.jpain.2014.08.010.
  4. ↑ Edmond I Eger II, Lawrence Saidman, Rod Westhorpe. The Wondrous Story of Anesthesia. Springer Science & Business Media, 2013 ISBN 9781461484417
  5. ↑ WHO Technical Report Series No. 211. 1961 Expert Committee on Addiction-Producing Drugs. Eleventh Report.
  6. ↑ WHO Executive Board. 17 April, 1961 Action in Respect of the International Convention on Narcotic Drugs.
  7. ↑ "Memo: Overview of the September 14, 2010, DSaRM Advisory Committee Meeting to Discuss the Drug Enforcement Administration (DEA) Request for an Abuse Potential Evaluation and Scheduling Recommendation for Dextromethorphan (DXM)" (PDF). U.S. Food and Drug Administration. U.S. Food and Drug Administration. Retrieved 22 November 2014.

External links


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.